Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:35:24.839Z.
Calculation as of: 2026-10-06T16:35:24.839Z.
Quote observation: 2026-10-06T16:35:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f621ea2a381ac0066d385c57ed104ff22630177ee14cd635e65ed0429d7856c2
PE RATIO
N/A
Market Cap
$538.54M
PE Ratio
1200.00
TTM Avg
806.49
3Y Avg
715.80
5Y Avg
715.80
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $546.08M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $544.69M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $542.14M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $539.30M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $538.54M | 1200.00 | 806.49 | 715.80 | 715.80 |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | N/A | N/A | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $528.79M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $564.94M | N/A | 80.35 | 49.81 | 49.81 |
| CorMedix Inc. (CRMD)vs › | $566.84M | 3.39 | 5.18 | 15.60 | 15.60 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.91
Forward EPS (Est.)
$-0.66
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
